ERCC1 and neoplasm: Of note, even though elevated ERCC1 levels are associated with resistance to platinum agents due to increased ICL repair,23 trial patients with high ERCC1 expression in their tumours derived the most clinical benefit from the addition of pevonedistat to carboplatin and paclitaxel.22